Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Michael Heuser et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Wilmer Flores et al.|Cancer Discovery|2018Cited by 570
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Michael J. Keating et al.|New England Journal of Medicine|2019Cited by 502
A human T cell-specific molecule is a member of a new gene family.Thomas J. Schall, Alan M. Krensky, Jan Jongstra et al.|The Journal of Immunology|1988Cited by 500